ISDA

Entry Detail

PDB ID:

6OD6

Keywords:

HYDROLASE/INHIBITOR

Title:

Structure of BACE-1 in complex with Ligand 13

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2019-03-26

Release Date:

2019-09-25

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.00 Å

R-Value Free:

0.24

R-Value Work:

0.22

R-Value Observed:

0.22

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Beta-secretase 1
Chain IDs:A, B, C
Chain Length:432
Number of Molecules:3
Biological Source:Homo sapiens

UniProt ID:P56817 Pfam ID:PF00026 EC:3.4.23.46

Ligand Molecules

GOL

M7D

Primary Citation

Evaluation of a Series of beta-Secretase 1 Inhibitors Containing Novel Heteroaryl-Fused-Piperazine Amidine Warheads.

Oehlrich, D, Peschiulli, A, Tresadern, G, Van Gool, M, Vega, J.A, De Lucas, A.I, Alonso de Diego, S.A, Prokopcova, H, Austin, N, Van Brandt, S, Surkyn, M, De Cleyn, M, Vos, A, Rombouts, F.J.R, Macdonald, G, Moechars, D, Gijsen, H.J.M, Trabanco, A.A.Show

Acs Med.Chem.Lett. 10 1159 1165 (2019)

PMID: 31413800 DOI: 10.1021/acsmedchemlett.9b00181

Abstact

Despite several years of research, only a handful of β-secretase (BACE) 1 inhibitors have entered clinical trials as potential therapeutics against Alzheimer's disease. The intrinsic basic nature of low molecular weight, amidine-containing BACE 1 inhibitors makes them far from optimal as central nervous system drugs. Herein we present a set of novel heteroaryl-fused piperazine amidine inhibitors designed to lower the basicity of the key, enzyme binding, amidine functionality. This study resulted in the identification of highly potent (IC50 ≤ 10 nM), permeable lead compounds with a reduced propensity to suffer from P-glycoprotein-mediated efflux.

Legend

Protein

Chemical

Disease

Primary Citation of related structures